phase readout

NCT07310420: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

RECRUITINGupdated 11h ago

community read0 votes

Sponsor: TerSera Therapeutics LLC. Phase: PHASE1. Conditions: Advanced Breast Cancer

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 9h ago

Found something off?